ID: MRFR/HC/7311-CR | February 2020 | Region: Global | 78 pages
Chemiluminescence Immunoassay Analyzers Market is expected to register a CAGR of 6.4% to reach USD 8,205.22 Million till 2026.
The chemiluminescence immunoassay (CLIA) analyzer is an instrument that is used for the detection and monitoring of chronic disorders. It plays a very important role in patient care and provides physicians with the required information to identify and treat various disorders. These chemiluminescence immunoassays (CLIA) analyzers are used to carry out the diagnosis of various diseases such as inherited genetic disease, infectious disease, and cardiovascular disease among others. It helps physicians with better treatment scenarios and even personalized treatment and prognostic investigations based upon individual genetic make-up. Results from chemiluminescence immunoassay (CLIA) analyzers help the physician to understand disease etiology, pathogenesis, diagnosis, and prognosis.
The key factors driving the market growth are increasing prevalence of chronic and acute diseases, increasing technological advancements, high specificity provided by chemiluminescence immunoassay (CLIA) analyzers.
However, the scarcity of skilled labor/healthcare professionals and stringent regulatory policies are the factors posing hurdles to the market growth at the global level.
Increasing prevalence of chronic and acute diseases is one of the key factors driving market growth. Rapid changes in lifestyle and eating habits in the social system over the last few years have accelerated the spread of chronic ailments such as cancer and other diseases such as cardiovascular disorders and neurological disorders, especially in developing countries. According to the World Health Organization (WHO), the number of deaths by coronary heart disease reached 23,624 or 24.25% of the total deaths in Saudi Arabia, in 2017. The growing prevalence of several chronic and acute diseases has led to the increasing demand for multiplex assays worldwide.
According to the National Cancer Institute, in 2016, around 1,685,210 new cases of cancer were diagnosed in the US. Additionally, as stated by the US Department of Health and Human Services, the incidence rate of cancer in the US was 439.2 per 100,000 men and women in 2015. Similarly, WHO reported that there are 3.7 million cases of cancer in Europe every year. Cancer is the leading cause of death globally. As per a survey carried out by the World Health Organization (WHO), around 9.6 million deaths caused by cancer were recorded in 2018 globally. Around 70% of the deaths from cancer were recorded in low- and middle-income countries. With the increasing prevalence of cancer in recent years, the demand for chemiluminescence immunoassay (CLIA) analyzers is also increasing.
The Chemiluminescence Immunoassay (CLIA) Analyzers Market is segmented into Type, Product, Application, and End User. By type, the market has been segmented into high throughput, medium-throughput, and low throughput. Based on product, the market has been segmented into reagents, analyzers, and consumables. The reagents are further classified into enzymatic markers and luminophore markers. By product, the analyzers are classified into automated and semi-automated. Based on the application, the chemiluminescence immunoassay (CLIA) analyzers market has been categorized as oncology & endocrinology, hepatitis and retroviruses, cardiac markers, infectious disease, bone and mineral disorders, auto-immune diseases, allergy, GI stool testing, drug discovery and development, and others. On the basis of end user, the market has been segmented into hospitals & clinics, medical & diagnostic laboratories, pharmaceutical companies, and others.
The Chemiluminescence Immunoassay (CLIA) Analyzers Market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
The Americas is expected to hold the largest share of the chemiluminescence immunoassay (CLIA) analyzers market. The growth of the American market can be attributed to the increasing prevalence of chronic diseases. For instance, the National Cancer Institute (NCI) had stated that 1,688,780 new cases of cancer were estimated during 2017 in the US. Thus, this increasing patient pool will enhance market growth during the forecast period. Rising expenses in research and development by healthcare institutions and government bodies is also one of the key contributing factors to the market growth.
Europe is expected to account for the second-largest market share during the forecast period. The European market for chemiluminescence immunoassay (CLIA) analyzers has been further segregated into Western Europe and Eastern Europe. Western Europe has been segmented into Germany, the UK, Italy, Spain, France, and the rest of Western Europe. Europe held a healthy share in the global chemiluminescence immunoassay (CLIA) analyzers market and is the second-largest market leader after the Americas, owing to the accessibility to advanced treatment facilities, rising government initiatives to promote research in chronic diseases, and high healthcare expenditure. For instance, according to Eurostat, the healthcare expenditure of Germany was EUR 352 billion in 2016.
Asia-Pacific is projected to witness the fastest growth rate during the forecast period owing to the huge patient pool suffering from chronic diseases as well as increasing government initiatives for healthcare reform. However, less capital investment and awareness regarding healthcare IT are some of the factors challenging market growth in this region.
The Prominent Players in the Chemiluminescence Immunoassay (CLIA) Analyzers Market are Mindray (China), Fujirebio (Japan), Autobio (China), Siemens AG Healthcare (Germany), Abbott Laboratories (US), Ortho Clinical Diagnostics (US), Tosoh Corporation (Japan), DiaSorin SpA (Italy), Beckman Coulter, Inc. (US), F. Hoffmann-La Roche Ltd (Switzerland), and Shenzhen New Industries Biomedical Engineering Co., Ltd (China) among others.
Some of the key strategies followed by players operating in the chemiluminescence immunoassay (CLIA) analyzers market were product innovation, software development, and acquisition & mergers.
Chemiluminescence Immunoassay Analyzers Market, by Type
Chemiluminescence Immunoassay (CLIA) Analyzers Market, by Product
Chemiluminescence Immunoassay (CLIA) Analyzers Market, by Application
Chemiluminescence Immunoassay Analyzers Market, by End User
Chemiluminescence Immunoassay (CLIA) Analyzers Market, by Region
Available Additional Customizations
|Market Size||2026: USD 8,205.22 Million|
|Forecast Units||Value (USD Million)|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, and Trends|
|Segments Covered||Type, Product, Application, End User|
|Geographies Covered||North America, Europe, Asia-Pacific, and Rest of the World (RoW)|
|Key Vendors||Mindray (China), Fujirebio (Japan), Autobio (China), Siemens AG Healthcare (Germany), Abbott Laboratories (US), Ortho Clinical Diagnostics (US), Tosoh Corporation (Japan), DiaSorin SpA (Italy), Beckman Coulter, Inc. (US), F. Hoffmann-La Roche Ltd (Switzerland), and Shenzhen New Industries Biomedical Engineering Co., Ltd (China) among others.|
|Key Market Opportunities||Rising demand for Chemiluminescence Immunoassay (CLIA) Analyzers|
|Key Market Drivers||
This table of content is tentative and subject to change as the research progresses.
Please Note: Financial details of company cannot be provided if the information of the company is not available in public domain and or reliable source.